Breaking Down SG&A Expenses: Eli Lilly and Company vs CymaBay Therapeutics, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and competitive edge. This analysis compares Eli Lilly and Company, a pharmaceutical giant, with CymaBay Therapeutics, Inc., a smaller biotech firm, from 2014 to 2023. Over this period, Eli Lilly's SG&A expenses have remained relatively stable, averaging around $6.4 billion annually, with a slight increase of about 5% in 2023. In contrast, CymaBay Therapeutics has seen a dramatic rise in SG&A expenses, surging by over 500% from 2014 to 2023. This growth reflects CymaBay's aggressive expansion and investment in marketing and administrative capabilities. The stark contrast in SG&A trends highlights the differing strategies and scales of these two companies, offering insights into their operational priorities and market positioning.